Piper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $48.00 (from $39.00), saying ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change Downgrades

Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA SubmissionAugust 7, 2015 8:36 AM Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15 August 7, 2015 6:56 AM Acadia Pharma (ACAD) Misses Q2 EPS by 6cAugust 6, 2015 4:15 PM ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial ResultsAugust 6, 2015 4:01 PM